Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 777-785

  Di Gioia, Dorit ^a   Heinemann, Volker ^a   Nagel, Dorothea ^a   Untch, Michael ^b   Kahlert, Steffen ^a   Bauerfeind, Ingo ^c   Koehnke, Thomas ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c Klinikum Landshut   (Germany)

Author keywords

CA15 3; CEA; Chemotherapy; Metastatic breast cancer; Tumour marker

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ELECTROCHEMICAL ANALYSIS; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 80052312067     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0180-7     Document Type: Article

References (23)

1. Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. (Pubitemid 40372904)
2. Jatoi I et al. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005;89(2):173-8. (Pubitemid 40249051)
3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14(10):2843-77.
4. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer (review). In Vivo. 1993;7 (6B):607-13.
5. Vizcarra E et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat. 1996;37(3):209-16.
6. Stieber P, Sauer H, Untch M. Tumor markers in breast cancer. J Lab Med. 2001;25(9/10):343-52. (Pubitemid 33101219)
7. Jaeger W et al. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anticancer Res. 2000;20 (6D):5179-82.
8. Molina R et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36(1):41-8.
9. Nicolini A et al. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991;64(1):154-8.
10. Molina R et al. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol. 2005;26 (6):281-93. (Pubitemid 41619458)
11. WHO. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication; 1979. No. 48.
12. Molina R et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat. 1998;51(2):109-19. (Pubitemid 28561416)
13. Gion M et al. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer. 1991;63 (5):809-13.
14. Robertson JF et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother. 1991;33(6):403-10.
15. Mughal AW et al. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. Jama. 1983;249(14):1881-6. (Pubitemid 13116495)
16. Robertson JF et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer. 1999;35(1):47-53. (Pubitemid 29079490)
17. Dixon AR et al. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction? Dis Markers. 1991;9(3-4):167-74.
18. Tondini C et al. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988;48(14):4107-12.
19. van Dalen A et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers. 1998;13(1):10-5. (Pubitemid 28356504)
20. Hayes DF et al. CA 15.3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clini Oncol. 1988;7:38a.
21. Yasasever V et al. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena. Clin Biochem. 1997;30(1):53-6. (Pubitemid 27097709)
22. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000;26(2):91-102. (Pubitemid 30182241)
23. Sjöström J et al. Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest. 2001;61 (6):431-41. (Pubitemid 32900430)